453 related articles for article (PubMed ID: 33320223)
1. Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
Antoszyk AN; Glassman AR; Beaulieu WT; Jampol LM; Jhaveri CD; Punjabi OS; Salehi-Had H; Wells JA; Maguire MG; Stockdale CR; Martin DF; Sun JK;
JAMA; 2020 Dec; 324(23):2383-2395. PubMed ID: 33320223
[TBL] [Abstract][Full Text] [Related]
2. Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
Glassman AR; Beaulieu WT; Maguire MG; Antoszyk AN; Chow CC; Elman MJ; Jampol LM; Salehi-Had H; Sun JK;
JAMA Ophthalmol; 2021 Jul; 139(7):725-733. PubMed ID: 33956075
[TBL] [Abstract][Full Text] [Related]
3. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
; Gross JG; Glassman AR; Jampol LM; Inusah S; Aiello LP; Antoszyk AN; Baker CW; Berger BB; Bressler NM; Browning D; Elman MJ; Ferris FL; Friedman SM; Marcus DM; Melia M; Stockdale CR; Sun JK; Beck RW
JAMA; 2015 Nov; 314(20):2137-2146. PubMed ID: 26565927
[TBL] [Abstract][Full Text] [Related]
4. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.
Diabetic Retinopathy Clinical Research Network*
JAMA Ophthalmol; 2013 Mar; 131(3):283-93. PubMed ID: 23370902
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.
Glassman AR; Baker CW; Beaulieu WT; Bressler NM; Punjabi OS; Stockdale CR; Wykoff CC; Jampol LM; Sun JK;
JAMA Ophthalmol; 2020 Apr; 138(4):341-349. PubMed ID: 32077907
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal Aflibercept injection with Panretinal photocoagulation versus early Vitrectomy for diabetic vitreous hemorrhage: randomized clinical trial.
Abd Elhamid AH; Mohamed AAEA; Khattab AM
BMC Ophthalmol; 2020 Apr; 20(1):130. PubMed ID: 32252674
[TBL] [Abstract][Full Text] [Related]
7. Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial.
Baker CW; Glassman AR; Beaulieu WT; Antoszyk AN; Browning DJ; Chalam KV; Grover S; Jampol LM; Jhaveri CD; Melia M; Stockdale CR; Martin DF; Sun JK;
JAMA; 2019 May; 321(19):1880-1894. PubMed ID: 31037289
[TBL] [Abstract][Full Text] [Related]
8. Changes in activity impairment and work productivity after treatment for vitreous hemorrhage due to proliferative diabetic retinopathy: Secondary outcomes from a randomized controlled trial (DRCR Retina Network Protocol AB).
Beaulieu WT; Maguire MG; Antoszyk AN;
PLoS One; 2023; 18(11):e0293543. PubMed ID: 37972038
[TBL] [Abstract][Full Text] [Related]
9. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
Gross JG; Glassman AR; Liu D; Sun JK; Antoszyk AN; Baker CW; Bressler NM; Elman MJ; Ferris FL; Gardner TW; Jampol LM; Martin DF; Melia M; Stockdale CR; Beck RW;
JAMA Ophthalmol; 2018 Oct; 136(10):1138-1148. PubMed ID: 30043039
[TBL] [Abstract][Full Text] [Related]
10. Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.
Maturi RK; Glassman AR; Josic K; Baker CW; Gerstenblith AT; Jampol LM; Meleth A; Martin DF; Melia M; Punjabi OS; Rofagha S; Salehi-Had H; Stockdale CR; Sun JK;
JAMA; 2023 Feb; 329(5):376-385. PubMed ID: 36749332
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.
Sivaprasad S; Prevost AT; Vasconcelos JC; Riddell A; Murphy C; Kelly J; Bainbridge J; Tudor-Edwards R; Hopkins D; Hykin P;
Lancet; 2017 Jun; 389(10085):2193-2203. PubMed ID: 28494920
[TBL] [Abstract][Full Text] [Related]
12. Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial.
Maturi RK; Glassman AR; Josic K; Antoszyk AN; Blodi BA; Jampol LM; Marcus DM; Martin DF; Melia M; Salehi-Had H; Stockdale CR; Punjabi OS; Sun JK;
JAMA Ophthalmol; 2021 Jul; 139(7):701-712. PubMed ID: 33784735
[TBL] [Abstract][Full Text] [Related]
13. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
; Wells JA; Glassman AR; Ayala AR; Jampol LM; Aiello LP; Antoszyk AN; Arnold-Bush B; Baker CW; Bressler NM; Browning DJ; Elman MJ; Ferris FL; Friedman SM; Melia M; Pieramici DJ; Sun JK; Beck RW
N Engl J Med; 2015 Mar; 372(13):1193-203. PubMed ID: 25692915
[TBL] [Abstract][Full Text] [Related]
14. Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.
Jhaveri CD; Glassman AR; Ferris FL; Liu D; Maguire MG; Allen JB; Baker CW; Browning D; Cunningham MA; Friedman SM; Jampol LM; Marcus DM; Martin DF; Preston CM; Stockdale CR; Sun JK;
N Engl J Med; 2022 Aug; 387(8):692-703. PubMed ID: 35833805
[TBL] [Abstract][Full Text] [Related]
15. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
Hutton DW; Stein JD; Glassman AR; Bressler NM; Jampol LM; Sun JK;
JAMA Ophthalmol; 2019 Dec; 137(12):1424-1432. PubMed ID: 31647496
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial.
Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Altaweel M; Berinstein DM;
JAMA Ophthalmol; 2018 Apr; 136(4):337-345. PubMed ID: 29476687
[TBL] [Abstract][Full Text] [Related]
17. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.
Martinez-Zapata MJ; Salvador I; Martí-Carvajal AJ; Pijoan JI; Cordero JA; Ponomarev D; Kernohan A; Solà I; Virgili G
Cochrane Database Syst Rev; 2023 Mar; 3(3):CD008721. PubMed ID: 36939655
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of intravitreal aflibercept injection versus vitrectomy with panretinal photocoagulation for patients with proliferative diabetic retinopathy: A protocol for systematic review and meta-analysis.
Hu Y; Shen J; Peng Y
Medicine (Baltimore); 2021 Apr; 100(14):e25354. PubMed ID: 33832114
[TBL] [Abstract][Full Text] [Related]
19. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy.
Yang CS; Hung KC; Huang YM; Hsu WM
J Ocul Pharmacol Ther; 2013; 29(6):550-5. PubMed ID: 23495932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]